Evidence map›Paper›PMID 39839297›Full record

ArticleFrontiers in nutrition2024

NAFPD exacerbation by hyperlipidemia combined with hyperuricemia: a pilot rat experiment in lipidomics.

Jingyun Li, Yongjian Chen, Shilin Li, Guorong Lyu, Furong Yan, Jiajing Guo, Jing Cheng, Yun Chen, Jiaojiao Lin, Yating Zeng

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in nutrition, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jingyun LiDepartment of Ultrasound, Second Affiliated Hospital of Fujian Medical University, Quanzhou, Fujian, China.
Yongjian ChenDepartment of Ultrasound, Second Affiliated Hospital of Fujian Medical University, Quanzhou, Fujian, China.
Shilin LiDepartment of Ultrasound, Second Affiliated Hospital of Fujian Medical University, Quanzhou, Fujian, China.
Guorong LyuDepartment of Ultrasound, Second Affiliated Hospital of Fujian Medical University, Quanzhou, Fujian, China.
Furong YanDepartment of Molecular Diagnostics Research Center, Second Affiliated Hospital of Fujian Medical University, Quanzhou, Fujian, China.
Jiajing GuoDepartment of Pathology, The 910th Hospital of the People's Liberation Army, Quanzhou, Fujian, China.
Jing ChengDepartment of Animal Experimental Center, Quanzhou Medical College, Quanzhou, Fujian, China.
Yun ChenDepartment of Internal Medicine, Quanzhou Medical College, Quanzhou, Fujian, China.
Jiaojiao LinDepartment of Ultrasound, Second Affiliated Hospital of Fujian Medical University, Quanzhou, Fujian, China.
Yating ZengDepartment of Ultrasound, Second Affiliated Hospital of Fujian Medical University, Quanzhou, Fujian, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Hyperuricemia and non-alcoholic fatty pancreas disease (NAFPD) are prevalent metabolic diseases, but the relationship between them remains underexplored. Methods: Eighteen Sprague-Dawley rats were randomly assigned to three groups: normal (CON), high-fat (PO), and high-fat high-uric acid (PH). After 12 weeks, serum uric acid (SUA) and triacylglycerol levels were measured. Pathological changes in the pancreas were assessed using hematoxylin-eosin (HE) staining. Serum samples were analyzed using lipidomics technology, and multivariate statistical analysis was employed to identify differences in lipid metabolism. Results: SUA levels in the PO group were not significantly different from those in the CON group ( Conclusion: Hyperlipidemia combined with hyperuricemia might exacerbates NAFPD. Glycerophospholipids may serve as key biomarkers in this process, potentially linked to a chronic inflammatory response mediated by glycerophospholipids.

Indexed as

glycerophospholipidshyperuricemialipidomicsnon-alcoholic fatty liver diseasenon-alcoholic fatty pancreas disease

Identifiers

PMID39839297
PMCPMC11746073

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.